- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00113308
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
March 13, 2017 updated by: GlaxoSmithKline
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
This study is being conducted to find out if an investigational drug called GW406381 can help people with rheumatoid arthritis.
Study Overview
Study Type
Interventional
Enrollment (Actual)
2208
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Ciudad Autónoma de Buenos Aires, Argentina, C1128AAF
- GSK Investigational Site
-
Ciudad Autónoma de Buenos Aires, Argentina, 1013
- GSK Investigational Site
-
Ciudad Autónoma de Buenos Aires, Argentina, 1427
- GSK Investigational Site
-
Ciudad Autónoma de Buenos Aires, Argentina, C1121ABE
- GSK Investigational Site
-
Ciudad Autónoma de Buenos Aires, Argentina, C1426BOR
- GSK Investigational Site
-
Cordoba, Argentina, 5000
- GSK Investigational Site
-
Quilmes, Argentina, 1878
- GSK Investigational Site
-
San Juan, Argentina, 5400
- GSK Investigational Site
-
Tucuman, Argentina, 4000
- GSK Investigational Site
-
-
Córdova
-
Cordoba, Córdova, Argentina
- GSK Investigational Site
-
Córdoba, Córdova, Argentina, 5000
- GSK Investigational Site
-
-
Santa Fe
-
Rosario, Santa Fe, Argentina, 2000
- GSK Investigational Site
-
-
-
-
-
Vienna, Austria, A-1021
- GSK Investigational Site
-
Vienna, Austria, A-1060
- GSK Investigational Site
-
Vienna, Austria, A-1090
- GSK Investigational Site
-
Vienna, Austria, A-1100
- GSK Investigational Site
-
-
-
-
-
Antwerpen, Belgium, 2020
- GSK Investigational Site
-
Diepenbeek, Belgium, 3590
- GSK Investigational Site
-
Lommel, Belgium, 3920
- GSK Investigational Site
-
Mons, Belgium, 7000
- GSK Investigational Site
-
-
-
-
-
Pleven, Bulgaria, 5800
- GSK Investigational Site
-
Sofia, Bulgaria, 1431
- GSK Investigational Site
-
Sofia, Bulgaria, 1233
- GSK Investigational Site
-
Sofia, Bulgaria, 1431/1000
- GSK Investigational Site
-
Varna, Bulgaria, 9010
- GSK Investigational Site
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T5K 2A2
- GSK Investigational Site
-
-
British Columbia
-
Penticton, British Columbia, Canada, V2A 3G8
- GSK Investigational Site
-
Victoria, British Columbia, Canada, V8P 5P6
- GSK Investigational Site
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3A 1M3
- GSK Investigational Site
-
-
Newfoundland and Labrador
-
Saint John's, Newfoundland and Labrador, Canada, A1B 3E1
- GSK Investigational Site
-
-
Ontario
-
Kitchener, Ontario, Canada, N2M 5N6
- GSK Investigational Site
-
Mississauga, Ontario, Canada, L5M 2V8
- GSK Investigational Site
-
Toronto, Ontario, Canada, M4N 3M5
- GSK Investigational Site
-
Toronto, Ontario, Canada, M5T 2S8
- GSK Investigational Site
-
Toronto, Ontario, Canada, M9W 4L6
- GSK Investigational Site
-
Windsor, Ontario, Canada, N8X 5A6
- GSK Investigational Site
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- GSK Investigational Site
-
Montreal, Quebec, Canada, H3Z 2Z3
- GSK Investigational Site
-
Sainte-Foy, Quebec, Canada, G1W 4R4
- GSK Investigational Site
-
St-Jerome, Quebec, Canada, J7Z 5T3
- GSK Investigational Site
-
Trois-Rivieres, Quebec, Canada, G8Z 1Y2
- GSK Investigational Site
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada, S7N 0W8
- GSK Investigational Site
-
-
-
-
Región Metro De Santiago
-
Santiago, Región Metro De Santiago, Chile, 8380456
- GSK Investigational Site
-
Santiago, Región Metro De Santiago, Chile
- GSK Investigational Site
-
-
Valparaíso
-
Viña del Mar, Valparaíso, Chile
- GSK Investigational Site
-
-
-
-
-
San Jose, Costa Rica
- GSK Investigational Site
-
-
-
-
-
Aalborg, Denmark, 9000
- GSK Investigational Site
-
Ishoj, Denmark, 2635
- GSK Investigational Site
-
Odense C, Denmark, 5000
- GSK Investigational Site
-
Vejle, Denmark, 7100
- GSK Investigational Site
-
-
-
-
-
Helsinki, Finland, 00100
- GSK Investigational Site
-
Hyvinkaa, Finland, 05800
- GSK Investigational Site
-
Kuopio, Finland, 70100
- GSK Investigational Site
-
-
-
-
-
Angers, France, 49100
- GSK Investigational Site
-
Cahors cedex 9, France, 46005
- GSK Investigational Site
-
Chilly Mazarin, France, 91380
- GSK Investigational Site
-
Corbeil Essonnes Cedex, France, 91106
- GSK Investigational Site
-
Grenoble cedex 09, France, 38042
- GSK Investigational Site
-
Lyon, France, 69002
- GSK Investigational Site
-
Paris cedex 12, France, 75571
- GSK Investigational Site
-
Toulouse, France, 31300
- GSK Investigational Site
-
Tours, France, 37000
- GSK Investigational Site
-
-
-
-
-
Berlin, Germany, 14057
- GSK Investigational Site
-
Berlin, Germany, 10777
- GSK Investigational Site
-
Berlin, Germany, 12247
- GSK Investigational Site
-
Berlin, Germany, 13125
- GSK Investigational Site
-
Berlin, Germany, 14109
- GSK Investigational Site
-
Hamburg, Germany, 22143
- GSK Investigational Site
-
Hamburg, Germany, 20249
- GSK Investigational Site
-
Hamburg, Germany, 22415
- GSK Investigational Site
-
-
Baden-Wuerttemberg
-
Baden-Baden, Baden-Wuerttemberg, Germany, 76530
- GSK Investigational Site
-
Deggingen, Baden-Wuerttemberg, Germany, 73326
- GSK Investigational Site
-
Freiburg, Baden-Wuerttemberg, Germany, 79098
- GSK Investigational Site
-
Kippenheim, Baden-Wuerttemberg, Germany, 77971
- GSK Investigational Site
-
Stuttgart, Baden-Wuerttemberg, Germany, 70469
- GSK Investigational Site
-
Stuttgart, Baden-Wuerttemberg, Germany, 66111
- GSK Investigational Site
-
Weinheim, Baden-Wuerttemberg, Germany, 69469
- GSK Investigational Site
-
-
Bayern
-
Bayreuth, Bayern, Germany, 95445
- GSK Investigational Site
-
Erlangen, Bayern, Germany, 91054
- GSK Investigational Site
-
Muenchen, Bayern, Germany, 80339
- GSK Investigational Site
-
Muenchen, Bayern, Germany, 80333
- GSK Investigational Site
-
Nuernberg, Bayern, Germany, 90402
- GSK Investigational Site
-
Passau, Bayern, Germany, 94032
- GSK Investigational Site
-
-
Hessen
-
Huettenberg, Hessen, Germany, 35625
- GSK Investigational Site
-
Wiesbaden, Hessen, Germany, 65185
- GSK Investigational Site
-
-
Mecklenburg-Vorpommern
-
Schwerin, Mecklenburg-Vorpommern, Germany, 19055
- GSK Investigational Site
-
-
Niedersachsen
-
Einbeck, Niedersachsen, Germany, 37574
- GSK Investigational Site
-
Hannover, Niedersachsen, Germany, 30519
- GSK Investigational Site
-
Hildesheim, Niedersachsen, Germany, 31134
- GSK Investigational Site
-
-
Nordrhein-Westfalen
-
Aachen, Nordrhein-Westfalen, Germany, 52064
- GSK Investigational Site
-
Beckum, Nordrhein-Westfalen, Germany, 59269
- GSK Investigational Site
-
Bochum, Nordrhein-Westfalen, Germany, 44787
- GSK Investigational Site
-
Essen, Nordrhein-Westfalen, Germany, 45326
- GSK Investigational Site
-
Goch, Nordrhein-Westfalen, Germany, 47574
- GSK Investigational Site
-
Hattingen, Nordrhein-Westfalen, Germany, 45525
- GSK Investigational Site
-
Koeln, Nordrhein-Westfalen, Germany, 51069
- GSK Investigational Site
-
Muenster, Nordrhein-Westfalen, Germany, 48155
- GSK Investigational Site
-
Witten, Nordrhein-Westfalen, Germany, 58455
- GSK Investigational Site
-
-
Rheinland-Pfalz
-
Rhaunen, Rheinland-Pfalz, Germany, 55624
- GSK Investigational Site
-
-
Saarland
-
Saarbruecken, Saarland, Germany, 66111
- GSK Investigational Site
-
-
Sachsen
-
Chemnitz, Sachsen, Germany, 09111
- GSK Investigational Site
-
Delitzsch, Sachsen, Germany, 04509
- GSK Investigational Site
-
Dresden, Sachsen, Germany, 01067
- GSK Investigational Site
-
Freital, Sachsen, Germany, 01705
- GSK Investigational Site
-
Goerlitz, Sachsen, Germany, 02826
- GSK Investigational Site
-
Leipzig, Sachsen, Germany, 04107
- GSK Investigational Site
-
Leipzig, Sachsen, Germany, 04229
- GSK Investigational Site
-
Schmiedeberg, Sachsen, Germany, 01762
- GSK Investigational Site
-
-
Sachsen-Anhalt
-
Wolmirstedt, Sachsen-Anhalt, Germany, 39326
- GSK Investigational Site
-
-
Schleswig-Holstein
-
Elmshorn, Schleswig-Holstein, Germany, 25335
- GSK Investigational Site
-
Luebeck, Schleswig-Holstein, Germany, 23538
- GSK Investigational Site
-
Pinneberg, Schleswig-Holstein, Germany, 25421
- GSK Investigational Site
-
-
-
-
-
Kavala, Greece, 65403
- GSK Investigational Site
-
Thessaloniki, Greece, 546 36
- GSK Investigational Site
-
Thessaloniki, Greece, 54642
- GSK Investigational Site
-
Thessaloniki, Greece, 564 29
- GSK Investigational Site
-
-
-
-
-
Budapest, Hungary, 1023
- GSK Investigational Site
-
Budapest, Hungary, 1238
- GSK Investigational Site
-
Budapest, Hungary
- GSK Investigational Site
-
Győr, Hungary, 9024
- GSK Investigational Site
-
-
-
-
-
Bangalore, India, 560 054
- GSK Investigational Site
-
Bangalore, India, 560 017
- GSK Investigational Site
-
Bangalore, India, 560034
- GSK Investigational Site
-
Chennai, India, 600003
- GSK Investigational Site
-
Hyderabad, India, 500 004
- GSK Investigational Site
-
Hyderabad, Andhra Pradesh, India, 500482
- GSK Investigational Site
-
New Delhi, India
- GSK Investigational Site
-
Pune., India, 411 001
- GSK Investigational Site
-
-
-
-
-
Dublin, Ireland, 9
- GSK Investigational Site
-
Waterford, Ireland
- GSK Investigational Site
-
-
-
-
Abruzzo
-
Pescara, Abruzzo, Italy, 65100
- GSK Investigational Site
-
-
Campania
-
Benevento, Campania, Italy, 82100
- GSK Investigational Site
-
Telese Terme (BN), Campania, Italy, 82100
- GSK Investigational Site
-
-
Liguria
-
Arenzano (GE), Liguria, Italy, 16011
- GSK Investigational Site
-
Genova, Liguria, Italy, 16148
- GSK Investigational Site
-
-
Lombardia
-
Rozzano (MI), Lombardia, Italy, 20089
- GSK Investigational Site
-
-
Toscana
-
Pisa, Toscana, Italy, 56126
- GSK Investigational Site
-
Prato, Toscana, Italy, 59100
- GSK Investigational Site
-
-
Umbria
-
Terni, Umbria, Italy, 05100
- GSK Investigational Site
-
-
Veneto
-
Montebelluna (TV), Veneto, Italy, 31044
- GSK Investigational Site
-
-
-
-
-
Anyang-Si, Korea, Republic of, 431-070
- GSK Investigational Site
-
Daegu, Korea, Republic of, 705-718
- GSK Investigational Site
-
Seoul, Korea, Republic of, 120-752
- GSK Investigational Site
-
Seoul, Korea, Republic of, 138-736
- GSK Investigational Site
-
Seoul, Korea, Republic of, 110-744
- GSK Investigational Site
-
Seoul, Korea, Republic of
- GSK Investigational Site
-
-
-
-
-
Liepaja, Latvia, LV3400
- GSK Investigational Site
-
Riga, Latvia, LV 1002
- GSK Investigational Site
-
Riga, Latvia, LV1079
- GSK Investigational Site
-
Valmiera, Latvia
- GSK Investigational Site
-
-
-
-
-
Mexico, Mexico, 06700
- GSK Investigational Site
-
Mexico, Mexico
- GSK Investigational Site
-
Mexico, D.F., Mexico, 06720
- GSK Investigational Site
-
-
Jalisco
-
Guadalajara, Jalisco, Mexico, 44280
- GSK Investigational Site
-
Guadalajara, Jalisco, Mexico, 44340
- GSK Investigational Site
-
-
Nuevo León
-
Monterrey, Nuevo León, Mexico, 64020
- GSK Investigational Site
-
-
-
-
-
Den Haag, Netherlands, 2597 AX
- GSK Investigational Site
-
Etten-leur, Netherlands, 4872 LA
- GSK Investigational Site
-
Gouda, Netherlands, 2803 HH
- GSK Investigational Site
-
Heerlen, Netherlands, 6416 EG
- GSK Investigational Site
-
Nijmegen, Netherlands, 6525 GA
- GSK Investigational Site
-
Zwolle, Netherlands, 8011 JW
- GSK Investigational Site
-
-
-
-
-
Auckland, New Zealand, 1701
- GSK Investigational Site
-
Auckland, New Zealand, 1309
- GSK Investigational Site
-
Christchurch, New Zealand, 8001
- GSK Investigational Site
-
Lower Hutt, New Zealand, 6009
- GSK Investigational Site
-
Rotorua, New Zealand, 3201
- GSK Investigational Site
-
-
-
-
-
Harstad, Norway, 9480
- GSK Investigational Site
-
Levanger, Norway, 7600
- GSK Investigational Site
-
Lillehammer, Norway, 2609
- GSK Investigational Site
-
Skien, Norway, 3722
- GSK Investigational Site
-
Tønsberg, Norway, N-3117
- GSK Investigational Site
-
-
-
-
-
Callao, Peru, Callao 2
- GSK Investigational Site
-
Lima, Peru, Lima 27
- GSK Investigational Site
-
Lima, Peru, Lima 39
- GSK Investigational Site
-
-
-
-
-
Manila, Philippines, 1000
- GSK Investigational Site
-
Manila, Philippines, 1003
- GSK Investigational Site
-
-
-
-
-
Grudziadz, Poland, 86-300
- GSK Investigational Site
-
Poznan, Poland, 61-544
- GSK Investigational Site
-
Warszawa, Poland, 02-341
- GSK Investigational Site
-
Wroclaw, Poland, 50-044
- GSK Investigational Site
-
Wroclaw, Poland, 50-088
- GSK Investigational Site
-
-
-
-
-
Caguas, Puerto Rico, 00726
- GSK Investigational Site
-
-
-
-
-
Brasov, Romania, 500366
- GSK Investigational Site
-
Bucharest, Romania, 11172
- GSK Investigational Site
-
Bucharest, Romania, 20983
- GSK Investigational Site
-
Bucharest, Romania
- GSK Investigational Site
-
-
-
-
-
Ekaterinburg, Russian Federation, 620102
- GSK Investigational Site
-
Moscow, Russian Federation, 119049
- GSK Investigational Site
-
Moscow, Russian Federation, 115522
- GSK Investigational Site
-
Moscow, Russian Federation, 129327
- GSK Investigational Site
-
Moscow, Russian Federation
- GSK Investigational Site
-
Ryazan, Russian Federation, 390026
- GSK Investigational Site
-
Sankt-Petersburg, Russian Federation
- GSK Investigational Site
-
Saratov, Russian Federation, 410053
- GSK Investigational Site
-
St. Petersburg, Russian Federation
- GSK Investigational Site
-
Tula, Russian Federation, 300053
- GSK Investigational Site
-
Yaroslavl, Russian Federation, 150003
- GSK Investigational Site
-
Yaroslavl, Russian Federation, 150062
- GSK Investigational Site
-
-
-
-
-
Cape Town, South Africa, 7525
- GSK Investigational Site
-
Durban, South Africa, 4001
- GSK Investigational Site
-
Erasmus Kloof, Pretoria, South Africa, 0048
- GSK Investigational Site
-
Kempton Park, South Africa, 1619
- GSK Investigational Site
-
Observatory, South Africa, 7925
- GSK Investigational Site
-
Pinetown, South Africa, 7405
- GSK Investigational Site
-
-
Eastern Cape
-
Korsten, Eastern Cape, South Africa, 6020
- GSK Investigational Site
-
-
Gauteng
-
Boksburg, Gauteng, South Africa
- GSK Investigational Site
-
Muckleneuk, Gauteng, South Africa, 0001
- GSK Investigational Site
-
Parktown, Gauteng, South Africa, 2193
- GSK Investigational Site
-
-
-
-
-
Baracaldo/Vizcaya, Spain, 48903
- GSK Investigational Site
-
Barcelona, Spain, 08025
- GSK Investigational Site
-
Barcelona, Spain, 08035
- GSK Investigational Site
-
Barcelona, Spain, 08003
- GSK Investigational Site
-
Cordoba, Spain, 14004
- GSK Investigational Site
-
Granada, Spain, 18014
- GSK Investigational Site
-
Guadalajara, Spain, 19002
- GSK Investigational Site
-
La Coruña, Spain, 15006
- GSK Investigational Site
-
Mérida (Badajoz), Spain, 06800
- GSK Investigational Site
-
Oviedo, Spain, 33006
- GSK Investigational Site
-
Pamplona, Spain, 31008
- GSK Investigational Site
-
San Sebastián, Spain, 20014
- GSK Investigational Site
-
Santiago de Compostela, Spain, 15706
- GSK Investigational Site
-
Sevilla, Spain, 41071
- GSK Investigational Site
-
Valencia, Spain, 46017
- GSK Investigational Site
-
Villajoyosa, Spain, 3570
- GSK Investigational Site
-
-
-
-
-
Kharkiv, Ukraine, 61039
- GSK Investigational Site
-
Kharkiv, Ukraine, 61002
- GSK Investigational Site
-
Kiev, Ukraine
- GSK Investigational Site
-
Kyiv, Ukraine, 03680
- GSK Investigational Site
-
Lviv, Ukraine, 79010
- GSK Investigational Site
-
-
-
-
Cornwall
-
Truro, Cornwall, United Kingdom, TR1 3LJ
- GSK Investigational Site
-
-
Hertfordshire
-
St Albans, Hertfordshire, United Kingdom, AL3 5PN
- GSK Investigational Site
-
-
Lancashire
-
Manchester, Lancashire, United Kingdom, M13 9WL
- GSK Investigational Site
-
-
Merseyside
-
Wirral, Merseyside, United Kingdom, CH49 9PE
- GSK Investigational Site
-
-
Middlesex
-
Ashford, Middlesex, United Kingdom, TW15 3AA
- GSK Investigational Site
-
-
Northamptonshire
-
Northampton, Northamptonshire, United Kingdom, NN1 5BD
- GSK Investigational Site
-
-
-
-
Alabama
-
Anniston, Alabama, United States, 36207
- GSK Investigational Site
-
Birmingham, Alabama, United States, 35205
- GSK Investigational Site
-
Birmingham, Alabama, United States, 35215
- GSK Investigational Site
-
Huntsville, Alabama, United States, 35801
- GSK Investigational Site
-
Montgomery, Alabama, United States, 36106
- GSK Investigational Site
-
Montgomery, Alabama, United States, 36111
- GSK Investigational Site
-
-
Arizona
-
Glendale, Arizona, United States, 85308
- GSK Investigational Site
-
Scottsdale, Arizona, United States, 85251
- GSK Investigational Site
-
Tucson, Arizona, United States, 85704
- GSK Investigational Site
-
Tucson, Arizona, United States, 85719
- GSK Investigational Site
-
-
California
-
Anaheim, California, United States, 92801
- GSK Investigational Site
-
Palm Desert, California, United States, 92260
- GSK Investigational Site
-
San Diego, California, United States, 92128
- GSK Investigational Site
-
San Diego, California, United States, 92103-6204
- GSK Investigational Site
-
San Diego, California, United States, 92108
- GSK Investigational Site
-
Santa Monica, California, United States, 90048
- GSK Investigational Site
-
Upland, California, United States, 91786
- GSK Investigational Site
-
-
Colorado
-
Colorado Springs, Colorado, United States, 80909
- GSK Investigational Site
-
-
Connecticut
-
Bridgeport, Connecticut, United States, 06606
- GSK Investigational Site
-
Danbury, Connecticut, United States, 06810
- GSK Investigational Site
-
Hamden, Connecticut, United States, 06518
- GSK Investigational Site
-
Trumbull, Connecticut, United States, 06611
- GSK Investigational Site
-
-
Florida
-
Aventura, Florida, United States, 33180
- GSK Investigational Site
-
Daytona Beach, Florida, United States, 32114
- GSK Investigational Site
-
Deland, Florida, United States, 32720
- GSK Investigational Site
-
Dunedin, Florida, United States, 34698
- GSK Investigational Site
-
Largo, Florida, United States, 33773
- GSK Investigational Site
-
Miami, Florida, United States, 33156
- GSK Investigational Site
-
Miami, Florida, United States, 33173
- GSK Investigational Site
-
Ocala, Florida, United States, 34474
- GSK Investigational Site
-
Orlando, Florida, United States, 32804
- GSK Investigational Site
-
Orlando, Florida, United States, 32806
- GSK Investigational Site
-
Palm Harbor, Florida, United States, 34684
- GSK Investigational Site
-
Port Orange, Florida, United States, 32127
- GSK Investigational Site
-
Stuart, Florida, United States, 34996
- GSK Investigational Site
-
Tampa, Florida, United States, 33614
- GSK Investigational Site
-
Trinity, Florida, United States, 34655
- GSK Investigational Site
-
West Palm Beach, Florida, United States, 33409
- GSK Investigational Site
-
Zephyrhills, Florida, United States, 33540
- GSK Investigational Site
-
-
Georgia
-
Atlanta, Georgia, United States, 30342
- GSK Investigational Site
-
Gainsville, Georgia, United States, 30501
- GSK Investigational Site
-
Roswell, Georgia, United States, 30075
- GSK Investigational Site
-
Woodstock, Georgia, United States, 30189
- GSK Investigational Site
-
-
Idaho
-
Idaho Falls, Idaho, United States, 83401
- GSK Investigational Site
-
-
Illinois
-
Evanston, Illinois, United States, 60201
- GSK Investigational Site
-
Morton Grove, Illinois, United States, 60053
- GSK Investigational Site
-
Springfield, Illinois, United States, 62704
- GSK Investigational Site
-
-
Indiana
-
Evansville, Indiana, United States, 47714
- GSK Investigational Site
-
Indianapolis, Indiana, United States, 46202
- GSK Investigational Site
-
Indianapolis, Indiana, United States, 46227
- GSK Investigational Site
-
-
Kansas
-
Prairie Village, Kansas, United States, 66206
- GSK Investigational Site
-
Wichita, Kansas, United States, 67207
- GSK Investigational Site
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- GSK Investigational Site
-
Louisville, Kentucky, United States, 40207
- GSK Investigational Site
-
Louisville, Kentucky, United States, 40213
- GSK Investigational Site
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70115
- GSK Investigational Site
-
Slidell, Louisiana, United States, 70458
- GSK Investigational Site
-
-
Maryland
-
Wheaton, Maryland, United States, 20902
- GSK Investigational Site
-
-
Massachusetts
-
Fall River, Massachusetts, United States, 02720
- GSK Investigational Site
-
Springfield, Massachusetts, United States, 01107
- GSK Investigational Site
-
-
Michigan
-
Kalamazoo, Michigan, United States, 49048
- GSK Investigational Site
-
Lansing, Michigan, United States, 48910
- GSK Investigational Site
-
-
Missouri
-
St. Louis, Missouri, United States, 63141
- GSK Investigational Site
-
St. Louis, Missouri, United States, 63117
- GSK Investigational Site
-
-
Nevada
-
Las Vegas, Nevada, United States, 89106
- GSK Investigational Site
-
Las Vegas, Nevada, United States, 89103
- GSK Investigational Site
-
Las Vegas, Nevada, United States, 89128
- GSK Investigational Site
-
Reno, Nevada, United States, 89502
- GSK Investigational Site
-
-
New Hampshire
-
Dover, New Hampshire, United States, 03820
- GSK Investigational Site
-
-
New Jersey
-
Berlin, New Jersey, United States, 08009
- GSK Investigational Site
-
Mercerville, New Jersey, United States, 08619
- GSK Investigational Site
-
-
New York
-
Johnson City, New York, United States, 13790
- GSK Investigational Site
-
Kingston, New York, United States, 12401
- GSK Investigational Site
-
New York, New York, United States, 10024
- GSK Investigational Site
-
North Massapequa, New York, United States, 11758
- GSK Investigational Site
-
Rochester, New York, United States, 14618
- GSK Investigational Site
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28210
- GSK Investigational Site
-
Gastonia, North Carolina, United States, 28054
- GSK Investigational Site
-
Hickory, North Carolina, United States, 28601
- GSK Investigational Site
-
Statesville, North Carolina, United States, 28625
- GSK Investigational Site
-
-
Ohio
-
Cleveland, Ohio, United States, 44130
- GSK Investigational Site
-
Columbus, Ohio, United States, 43210
- GSK Investigational Site
-
Concinnati, Ohio, United States, 45219
- GSK Investigational Site
-
Mayfield Village, Ohio, United States, 44143
- GSK Investigational Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73112
- GSK Investigational Site
-
Tulsa, Oklahoma, United States, 74135
- GSK Investigational Site
-
Tulsa, Oklahoma, United States, 74104
- GSK Investigational Site
-
-
Oregon
-
Medford, Oregon, United States, 97504
- GSK Investigational Site
-
-
Pennsylvania
-
Duncansville, Pennsylvania, United States, 16635
- GSK Investigational Site
-
Philadelphia, Pennsylvania, United States, 19140
- GSK Investigational Site
-
Philadelphia, Pennsylvania, United States, 19118
- GSK Investigational Site
-
West Reading, Pennsylvania, United States, 19611
- GSK Investigational Site
-
-
South Carolina
-
Charleston, South Carolina, United States, 29407
- GSK Investigational Site
-
Charleston, South Carolina, United States, 29406
- GSK Investigational Site
-
Greer, South Carolina, United States, 29651
- GSK Investigational Site
-
Hampton, South Carolina, United States, 29924
- GSK Investigational Site
-
Murrells Inlet, South Carolina, United States, 29576
- GSK Investigational Site
-
-
Tennessee
-
Memphis, Tennessee, United States, 38119
- GSK Investigational Site
-
-
Texas
-
Austin, Texas, United States, 78705
- GSK Investigational Site
-
Dallas, Texas, United States, 75231
- GSK Investigational Site
-
San Antonio, Texas, United States, 78229
- GSK Investigational Site
-
San Antonio, Texas, United States, 78232
- GSK Investigational Site
-
-
Washington
-
Everett, Washington, United States, 98201
- GSK Investigational Site
-
Vancouver, Washington, United States, 98664
- GSK Investigational Site
-
-
Wisconsin
-
Racine, Wisconsin, United States, 53404
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion criteria:
- Rheumatoid arthritis (RA) for at least 12 months.
- Required a non-steroidal anti-inflammatory drug (NSAID) or COX-2 inhibitor for RA for at least 5 out of 7 days of each week for the 4 weeks prior to screening.
Exclusion criteria:
- Any history of cardiovascular disease (e.g., heart attack, stroke, congestive heart failure, uncontrolled high blood pressure), documented peripheral arterial insufficiency and symptomatic, clinically significant claudication, or who have a history of peripheral arterial embolism.
- Have an active stomach ulcer or history of any stomach tear or bleeding.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percentage of American College of Rheumatology (ACR)20 Responders at Week 12
Time Frame: Week 12
|
Week 12
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change from baseline to each scheduled visit in tender/painful joint count (68 joint panel)
Time Frame: Baseline and Week 12
|
Baseline and Week 12
|
|
Change from baseline to each scheduled visit in swollen joint count (66 joint panel)
Time Frame: Baseline and Week 12
|
Baseline and Week 12
|
|
Change from baseline to each scheduled visit in patient's pain assessment (VAS)
Time Frame: Baseline and Week 12
|
Baseline and Week 12
|
|
Change from baseline to each scheduled visit in physician's global assessment of arthritis condition
Time Frame: Baseline and Week 12
|
Baseline and Week 12
|
|
Change from baseline to each scheduled visit in patient's global assessment of arthritis condition
Time Frame: Baseline and Week 12
|
Baseline and Week 12
|
|
Change from baseline to each scheduled visit in functional disability index (HAQ)
Time Frame: Baseline and Week 12
|
Baseline and Week 12
|
|
Change between baseline and end of treatment (or early withdrawal) in the Short Form - McGill Pain Questionnaire (SF-MPQ)
Time Frame: Baseline and Up to Week 12
|
Baseline and Up to Week 12
|
|
Change from baseline to each scheduled visit in C-reactive protein (CRP)
Time Frame: Baseline and up to Week 12
|
Baseline and up to Week 12
|
|
Number of participants withdrawing from the study due to lack of efficacy
Time Frame: Week 12
|
Week 12
|
|
Number of participants who received supplementary analgesic therapy
Time Frame: Week 12
|
Week 12
|
|
Changes from pretreatment to on treatment and post-treatment follow-up in vital signs- systolic blood pressure (SBP) and diastolic blood pressure (DBP)
Time Frame: Baseline and up to Week 12
|
Baseline and up to Week 12
|
|
Changes from pretreatment to on treatment and post-treatment follow-up in vital signs- heart rate (HR)
Time Frame: Baseline and up to Week 12
|
Baseline and up to Week 12
|
|
Changes from pretreatment to on treatment and post-treatment follow-up in weight
Time Frame: Baseline and Week 12
|
Baseline and Week 12
|
|
Number of participants with change in BMI of potential clinical concern
Time Frame: Week 4, 4, 8, 12 and foloow up
|
Week 4, 4, 8, 12 and foloow up
|
|
Number of participants with change from baseline of pedal oedema (including diuretic use)
Time Frame: Baseline and up to Week 12
|
Baseline and up to Week 12
|
|
Change from baseline in 12-lead electrocardiograms (ECGs)
Time Frame: Baseline and up to Week 12
|
Baseline and up to Week 12
|
|
Change from baseline in clinical chemistry parameters: Albumin
Time Frame: Baseline and up to Week 12
|
Baseline and up to Week 12
|
|
Change from baseline in clinical chemistry parameters: Alkaline Phosphatase, Alanine Amino Transferase, Aspartate Amino Transferase
Time Frame: Baseline and Up to Week 12
|
Baseline and Up to Week 12
|
|
Change from baseline in clinical chemistry parameters: Total Bilirubin
Time Frame: Baseline and up to Week 12
|
Baseline and up to Week 12
|
|
Change from baseline in clinical chemistry parameters: Carbon Dioxide content /Bicarbonate, Glucose, Potassium, Sodium
Time Frame: Baseline and up to Week 12
|
Baseline and up to Week 12
|
|
Change from baseline in clinical chemistry parameters: Creatinine
Time Frame: Baseline and up to Week 12
|
Baseline and up to Week 12
|
|
Change from baseline in haematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet count, White Blood Cell count
Time Frame: Baseline and up to Week 12
|
Baseline and up to Week 12
|
|
Change from baseline in haematology parameters: Hemoglobin
Time Frame: Baseline and up to Week 12
|
Baseline and up to Week 12
|
|
Change from baseline in haematology parameters: Mean Corpuscle volume
Time Frame: Baseline and Up to Week 12
|
Baseline and Up to Week 12
|
|
Change from baseline in haematology parameters: Red Blood Cell count
Time Frame: Baseline and up to Week 12
|
Baseline and up to Week 12
|
|
Urinalysis assessment
Time Frame: Up to Week 12
|
Up to Week 12
|
|
Number of participants with adverse events (AEs) and serious adverse events (SAEs)
Time Frame: Upto Week 12
|
Upto Week 12
|
|
Change in the Short Form-36 (SF-36v2) subscale scores between baseline and the end of treatment (or early withdrawal)
Time Frame: Baseline and Week 12
|
Baseline and Week 12
|
|
Change in the Short Form-36 (SF-36v2) Physical component summary score and mental component summary score between baseline and the end of treatment (or early withdrawal)
Time Frame: Baseline and Week 12
|
Baseline and Week 12
|
|
Psychometrically test and validate the amended Patient Satisfaction with Pain Medication questionnaire
Time Frame: Week 12
|
Week 12
|
|
Change between baseline and end of treatment (or early withdrawal) in the EuroQoL Questionnaire -5 Dimensions (EQ-5D) utility score, using European population utility tariff
Time Frame: Baseline and Week 12
|
Baseline and Week 12
|
|
Change between baseline and end of treatment (or early withdrawal) in the fatigue/inertia factor of the Profile of Moods States Brief Form (POMS-B)
Time Frame: Baseline and Week 12
|
Baseline and Week 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2005
Primary Completion (Actual)
September 1, 2006
Study Completion (Actual)
September 1, 2006
Study Registration Dates
First Submitted
June 7, 2005
First Submitted That Met QC Criteria
June 7, 2005
First Posted (Estimate)
June 8, 2005
Study Record Updates
Last Update Posted (Actual)
March 14, 2017
Last Update Submitted That Met QC Criteria
March 13, 2017
Last Verified
March 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CXA30009
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.